David Kabakoff, PhD
David shares his time between HealthQuest and Sofinnova Ventures, where he has been an investor since 2007. David joined the HealthQuest team to leverage decades of experience as an entrepreneur in the diagnostics field. While a chemist by training, the companies that David has led as President, CEO or Chairman have produced billions of dollars in returns for investors and employees. He currently serves on the Boards of portfolio companies Lineagen, Biotheranostics and Castle Biosciences.
As an operator, David’s successes include leading the development of some of the diagnostic industry’s most iconic products, like the first yes/no color changing pregnancy test, the PSA test for prostate cancer, and the rapid strep throat test, plus numerous cancer diagnostics. He served in senior executive positions at Hybritech and was EVP of Dura Pharmaceuticals, CEO of Spiros Development Corp. and Corvas International, and co-founder/CEO of Salmedix. Each of the products that he developed succeeded because it made a big impact on the medical management of patients; David keeps a keen eye out for the same quality when he considers investments for HealthQuest.
In addition to his HealthQuest Board responsibilities, David serves as a Board member of Antiva Biosciences and Dauntless Pharmaceuticals and as a Board Observer at Histogenics. He has served as Chairman of Trius Therapeutics (acquired by Cubist), Cebix Inc., and Amplimmune, Inc. (acquired by AstraZeneca) and as a Director of InterMune, Inc. (acquired by Roche) and Allylix, Inc. (acquired by Evolva).
David earned his BA in chemistry from Case Western Reserve University and then his PhD from Yale University. He lives with his wife in the San Diego area and enjoys fine wine, travel and skiing.